Charles Elliott Sigal

Insider Reports History

Reporting-owner location: Cambridge, MA
Latest reporting-owner signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Charles Elliott Sigal

Form 4 holding Director

ALNYLAM PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 2,000
Estimated value: $661,740
Report date: 20 May 2026
Price: $330.87
Ownership: by Trust

Form 4 holding Director

ALNYLAM PHARMACEUTICALS, INC.

Security class: Common Stock
Shares / value: 1,446
Estimated value: $478,438
Report date: 20 May 2026
Price: $330.87
Ownership: Direct

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Common Stock
Shares / value: 39,806
Estimated value: $356,661
Report date: 27 May 2026
Price: $8.96
Ownership: Direct

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Common Stock
Shares / value: 10,000
Estimated value: $89,600
Report date: 27 May 2026
Price: $8.96
Ownership: By Sigal Family Investments, LLC

Form 4 holding Director

Vir Biotechnology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 16,000
Estimated value: $24,480
Report date: 27 May 2026
Price: $1.53
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class: Option to purchase Ordinary Shares
Shares / value: 933,317
Estimated value
Report date: 03 Jul 2023
Price
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount

Form 4 holding Director

ALNYLAM PHARMACEUTICALS, INC.

Security class: Stock Option (Right to Buy)
Shares / value: 1,441
Estimated value
Report date: 20 May 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Surface Oncology, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 08 Sep 2023
Price: $0.9400
Ownership: Indirect

Form 4 holding Director

Surface Oncology, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 08 Sep 2023
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Charles Elliott Sigal

4 VIR

Vir Biotechnology, Inc.

Report period: 27 May 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 28 May 2026, 19:25
Role: Director
Next action: Open filing details

4 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 20 May 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 22 May 2026, 16:20
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 30 May 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 02 Jun 2025, 19:31
Role: Director
Next action: Open filing details

4 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 08 May 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 12 May 2025, 16:04
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 30 May 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Jun 2024, 12:18
Role: Director
Next action: Open filing details

4 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 16 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 May 2024, 16:08
Role: Director
Next action: Open filing details

4

Surface Oncology, Inc.

Report period: 08 Sep 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 08 Sep 2023, 16:00
Role: Director
Next action: Open filing details

4 ADAP

Adaptimmune Therapeutics PLC

Report period: 03 Jul 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Jul 2023, 17:02
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 22 May 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 24 May 2023, 14:33
Role: Director
Next action: Open filing details

4 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 18 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 May 2023, 16:06
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 01 Mar 2023
Transactions: 1
Transaction value: +$56,816
Accepted by SEC: 02 Mar 2023, 15:27
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 05 Jan 2023
Transactions: 1
Transaction value: +$62,396
Accepted by SEC: 09 Jan 2023, 10:51
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 03 Jan 2023
Transactions: 2
Transaction value: +$127,129
Accepted by SEC: 05 Jan 2023, 16:00
Role: Director
Next action: Open filing details

4 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 22 Aug 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 24 Aug 2022, 16:08
Role: Director
Next action: Open filing details

3 ALNY

ALNYLAM PHARMACEUTICALS, INC.

Report period: 22 Aug 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 24 Aug 2022, 16:07
Role: Director
Next action: Open filing details

4 ADAP

Adaptimmune Therapeutics PLC

Report period: 01 Jul 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Jul 2022, 17:01
Role: Director
Next action: Open filing details

4

Surface Oncology, Inc.

Report period: 08 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2022, 20:00
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 23 May 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 25 May 2022, 18:09
Role: Director
Next action: Open filing details

4 ADAP

Adaptimmune Therapeutics PLC

Report period: 01 Jul 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 02 Jul 2021, 17:01
Role: Director
Next action: Open filing details

4

Surface Oncology, Inc.

Report period: 08 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 10 Jun 2021, 16:30
Role: Director
Next action: Open filing details

4 VIR

Vir Biotechnology, Inc.

Report period: 21 May 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 25 May 2021, 16:48
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .